

# CONTENTS

<b>LIST OF FIGURES</b>	<b>i</b>
<b>LIST OF TABLES</b>	<b>viii</b>
<b>LIST OF ABBREVIATED TERMS</b>	<b>ix</b>
<b>ABSTRACT</b>	<b>x</b>
<b>CHAPTER-1</b>	<b>1-7</b>
<b>INTRODUCTION</b>	
<b>CHAPTER-2</b>	<b>8-84</b>
<b>LITERATURE REVIEW</b>	
<b>2.1 Medicinal plants with application in wound healing activity</b>	
<b>2.2 Major groups of antimicrobial compounds from plants</b>	
<b>2.3 Herbs with potential wound healing activity</b>	
<b>2.4 Microorganisms commonly associated with diabetic wound</b>	
<b>2.5 Wound Healing: General Consideration</b>	
<b>2.5.1 Wounds and wound types</b>	
<b>Acute Wounds</b>	
<b>Chronic Wounds</b>	
<b>Complicated wounds</b>	
<b>2.5.2 Types of Wound Healing</b>	
<b>Primary Healing</b>	

**Secondary Healing**

**Delayed Primary Healing**

**2.5.3 Wound Repair Monitoring & Models**

**2.5.4 General Wound Healing Process**

**Haemostasis & Inflammation**

**Proliferation**

**Maturation and Remodeling**

**Wound Contraction**

**2.5.5 Factors influencing wound healing**

**General Factor**

**Specific Factor**

**2.5.5 How Wound Healing In Diabetes Differ From Normal**

**Wound Healing**

**CHAPTER-3**

**85-103**

**MATERIAL AND METHODOLOGY**

**3.1 Materials**

**3.1.1 Procurement of Chemicals**

**3.1.2 Procurement of Plant Material**

**3.1.3 Procurement Microorganisms**

**3.1.4 Procurement and Maintenance of Animals**

**3.1.5 Preparation and Maintenance of Stock Cultures**

**3.1.6 Culture Media**

**3.2 Methods**

**3.2A Methods (*Invitro*)**

**3.2.1a Extraction of Plant Material**

**3.2.2 a Preparation of Plant extracts Stock Concentrations**

**3.2.3 a Preparation of Inocula**

**3.2.4 a Qualitative Phytochemical Aanalysis**

**3.2.5 a Antimicrobial Activity Screening Test**

**3.2.6 a Minimum Inhibitory Concentration Determination**

**3.2.7 a Preparation of Herbal Formulations**

**3.2B Methods (*Invivo*)**

**3.2.1b Induction of Diabetes in Rats**

**3.2.2 b Skin IrritationStudies**

**3..2.3 b Excision Wound Model**

**3.2.4 b Group Division of Animals**

**3.2.5 b Dose Schedule and Treatment Period:**

**3.2.6 b Wound Healing Study Parameter by ExcisionWound Model**

**Assesment of Wound Contraction**

**Period of Epithelialization**

**Histological Study of Healed Section of Wounded Area**

**3.2.7 b Analysis of Data**

**CHAPTER-4**

**104-170**

**RESULTS**

#### **4.1 Ethanollic Extraction of Plant Material**

#### **4.2. Qualitative Phytochemical Analysis**

##### **4.2.1 Qualitative Phytochemical Analysis of Selected Plant Extracts**

##### **4.2.2 Qualitative Phytochemical Analysis of Natural Compounds**

#### **4.3 Evaluation of Antimicrobial Activity**

##### **4.3.1 Evaluation of Antimicrobial Activity of Selected Plant Extracts**

##### **4.3.2 Evaluation of Antimicrobial Activity of natural Compounds**

#### **4.4 Determination of Minimum Inhibitory Concentration (MIC)**

##### **4.4.1 Determination of Minimum Inhibitory Concentration Of Slected Plant Extracts**

##### **4.4.2 Determination of Minimum Inhibitory Concentration of Selected Natural Compounds**

#### **4.5 Evaluation of Wound Healing Activity by Excision Wound Model**

##### **4.5.1 Average Mean Wound Area Closure**

##### **4.5.2 Percent Wound Closure**

##### **4.5.3 Evaluation of Period of Epithelialization**

##### **4.5.4. Histological Study of Healed Skin**

## **CHAPTER-5**

**171-181**

### **DISCUSSION**

#### **5.1 Extraction of Plant Material**

**5.2 Detection of Nature of Phytochemical in Plant Products**

**5.3 Antimicrobial Activities**

**5.4 Minimum Inhibitory Concentrations**

**5.5 Wound Healing Activities**

**5.5.1 Wound Contraction**

**5.5.2 Period of Epithelialization**

**5.5.3 Histological Observation of Healed Skin**

**CHAPTER-6**

**181-184**

**SUMMARY AND CONCLUSION**

**REFERENCES**

**185-198**

**LIST OF PUBLICATIONS**

**199**

## LIST OF TABLES

S. No.	Table	page no.
1.	<b>Table 2.1 Comparison between synthetic and phytomedicines</b>	32
2.	<b>Table 2.2 Percentage Frequency of Individual Bacteria and Fungi in Ulceration of Diabetic Origin(Kucharzewski <i>et. al.</i> 2005).</b>	47
3.	<b>Table 2.3. Phases of wound healing</b>	66
4.	<b>Table 2.4 Effect of nutrition on wound healing</b>	69
5.	<b>Table 2.5 Growth factors present during wound repair</b>	73
6.	<b>Table 3.1 (a)Plants collected from field</b>	77
7.	<b>Table 3.1 (b) Plants secured commercially</b>	77
8.	<b>Table 3.2 Composition for Nutrient Agar</b>	80
9.	<b>Table 3.3 Composition for Nutrient Broth</b>	80
10.	<b>Table 3.4 Composition for SabouraudDextone Agar (S.D.A)</b>	81
11.	<b>Table 3.5 Composition for Sabourand Dextrose Broth (S.D.B.)</b>	81
12.	<b>Table 3.6 Composition for Muller-Hinton Agar (M.H.A)</b>	81
13.	<b>Table 4.1 Percentage yield (w/w) of 95% ethanolic extracts of plants used in formulations</b>	93
14.	<b>Table 4.2 Qualitative phytochemical analysis of ethanolic fruit extract of <i>TerminaliaBellerica</i></b>	95
15.	<b>Table 4.3 Qualitative phytochemical analysis of ethanolic leaf extract</b>	95

	<b>of <i>Azadirachta indica</i></b>	
<b>16.</b>	<b>Table 4.4 Qualitative phytochemical analysis of ethanolic fruit extract of <i>Terminalia chebula</i></b>	06
<b>17.</b>	<b>Table 4.5 Qualitative phytochemical analysis of ethanolic leaves extract of <i>Centella asiatica</i></b>	96
<b>18.</b>	<b>Table 4.6 Qualitative phytochemical analysis of ethanolic extract of <i>Curcuma longa</i> rhizomes.</b>	97
<b>19.</b>	<b>Table 4.7 Qualitative phytochemical analysis of ethanolic fruit extract of <i>Phyllanthus emblica</i></b>	97
<b>20.</b>	<b>Table 4.8 Qualitative phytochemical analysis of ethanolic extract of <i>Aloevera leaf gel</i></b>	98
<b>21.</b>	<b>Table 4.9 Qualitative phytochemical analysis of Honey</b>	98
<b>22.</b>	<b>Table 4.10 Evaluation of anti microbial activity of <i>Azadirachta indica</i></b>	102
<b>23.</b>	<b>Table 4.11 Evaluation of anti microbial activity of <i>Terminalia Bellerica</i></b>	103
<b>24.</b>	<b>Table 4.12 Evaluation of anti microbial activity of <i>Terminalia chebula</i></b>	104
<b>25.</b>	<b>Table 4.13 Evaluation of anti microbial activity of <i>Centella asiatica</i></b>	105
<b>26.</b>	<b>Table 4.14 Evaluation of anti microbial activity of <i>Curcuma longa</i></b>	106
<b>27.</b>	<b>Table 4.15 Evaluation of anti microbial activity of <i>Phyllanthus emblica</i></b>	107

28.	Table 4.16 Evaluation of anti microbial activity of Streptomycin	108
29.	Table 4.18 Evaluation of anti microbial activity of Honey	109
30.	Table 4.19 Evaluation of anti microbial activity of <i>Aloevera</i> gel	110
31.	Table 4.20 MIC of plant extracts against <i>E. coli</i>	115
32.	Table 4.21 MIC of plant extracts against <i>Staphylococcus aureus</i>	117
33.	Table 4.22. MIC of plant extracts against <i>Pseudomonas aeruginosa</i>	118
34.	Table 4.23 MIC of plant extracts against <i>Proteus mirabilis</i>	120
35.	Table 4.24 MIC of selected plant extracts against <i>Candida albicans</i>	121
36.	Table 4.25 MIC of Honey against five tested microorganisms	123
37.	Table 4.26 MIC of <i>Aloevera</i> gel against five tested microorganisms	124
38.	Table 4.27 Evaluation of wound healing activity of test formulations	130
39.	Table -4.28% Wound Area Contraction	
40.	Table 4.29 Evaluation of period of epithelialization	

S. No.	Figure	Page no.
1.	Fig. 2.1 <i>Centella asiatica</i> (Leaves)	10
2.	Fig. 2.2 Phytochemical constituents of <i>Centella asiatica</i> (a) Asiticoside (b)	11



	<b>Madecassoside (c) Madecassic (d) Asiatic acid</b>	
<b>3.</b>	<b>Fig. 2.3 <i>Azadirachta indica</i> (Leaves)</b>	13
<b>4.</b>	<b>Fig. 2.4 Phytochemical constituents of <i>Azadirachta indica</i> (a) Azadirachtin (b) Nimbin (c) Nimocinol (d) Quercetin (e) Nimbinene</b>	14
<b>5.</b>	<b>Fig. 2.5 <i>Terminalia Bellerica</i> (Fruits)</b>	16
<b>6.</b>	<b>Fig. 2.6 Phytochemical constituents of <i>Terminalia bellerica</i> (a) Gallic acid (b) Ellagic acid (c) Beta-sitosterol (d) Chebulinic Acid (e) Tannic acid</b>	17
<b>7.</b>	<b>Fig. 2.7 <i>Terminalia chebula</i> (Fruits)</b>	19
<b>8.</b>	<b>Fig. 2.8 Phytochemical constituents of <i>Terminalia chebula</i> (a) Chebulagic acid (b) Chebulinic acid (c) Athraquinone (d) Sennoside (e) Tannic acid</b>	20
<b>9.</b>	<b>Fig. 2.9 <i>Phyllanthus emblica</i> (Fruits)</b>	22
<b>10.</b>	<b>Figure- 2.10 Phytochemical constituents of <i>Phyllanthus emblica</i>(a) <i>Emblicanin-A</i> (b)<i>Emblicanin-B</i> (c)<i>Pedunculagin</i> (d) Gallic acid (e) Methyn gallate (f) Punigluconin</b>	23
<b>11.</b>	<b>Fig. 2.11 <i>Curcuma longa</i> (Flower and Rhizomes)</b>	26
<b>12.</b>	<b>Fig. 2.12 Phytochemical constituents of <i>Curcuma longa</i></b>	27
<b>13.</b>	<b>Fig. 2.13 <i>Aloevera</i> (a) Leaves (b) Leaf gel</b>	29
<b>14.</b>	<b>Figure- 2.14 Phytochemical constituents of <i>Aloevera</i> (a) Veracylglucan A (b) Veracylglucan B (c) Veracylglucan C (d) A cemannan (e) Beta sitosterol</b>	30
<b>15.</b>	<b>Fig. 2.15 Honey</b>	32
<b>16.</b>	<b>Fig. 2.16 Phytochemical constituents of <i>Honey</i> (a) Pinocembrin (b)</b>	32

	Pinobanskin (c) Chrysin (d) Galagin (e) Acacetin (f) Quercetin (g) Kaempferol	
17.	Fig. 2.17 Microorganisms commonly associated with diabetic wound (a) <i>E-coli</i> (b) <i>S. aureus</i> (c) <i>P. aeruginosa</i> (d) <i>P. mirabilis</i> (e) <i>C. albicans</i>	53
18.	Fig. 2.18 Wound Healing Process	65
18.	Fig. 4.1 Mean zones of inhibition of ethanolic leaves extract of <i>Azadirachta indica</i> against tested pathogens.	112
19.	Fig. 4.2 Mean zones of inhibition of ethanolic fruit extract of <i>Terminalia bellerica</i> against tested pathogens.	113
20.	Fig. 4.3 Mean zones of inhibition of ethanolic fruit extract of <i>Terminalia chebula</i> against tested pathogens.	114
21.	Fig. 4.4 Mean zones of inhibition of ethanolic leave extract of <i>Centella asiatica</i> against tested pathogens.	115
22.	Fig. 4.5 Mean zones of inhibition of ethanolic extract of <i>Curcuma longa</i> against tested pathogens.	116
23.	Fig. 4.6 Mean zones of inhibition of of ethanolic fruit extract of <i>Phyllanthus emblica</i> against tested pathogens.	117
24.	Fig. 4.7 Mean zones of inhibition of Streptomycin against tested pathogens.	118
25.	Fig. 4.8 Mean zones of inhibition of Honey at 50%, 80%, 100% concentration.	119
26.	Fig. 4.9 Mean zones of inhibition of ethanolic extract of <i>Aloevera</i> gel against tested microorganism.	121
27.	Fig. 4.10. Inhabitation zones of ethanolic extract of six selected plant extracts against (a) <i>E.coli</i> (b) <i>S. aureus</i> (c) <i>P. mirabilis</i> (d) <i>P.aeruginosa</i> (e) <i>C. albicans</i> .	122
28.	Fig. 4.11. Inhibition zones of Honey at 50%,80%,100% concentration and ethanolic extracts of <i>Aloevera</i> leaf gel .	123
29.	Fig. 4.12. Inhibition zones of Honey at 50%,80%,100% concentration and ethanolic extracts of <i>Aloevera</i> leaf gel.	123

30.	Fig. 4.13. Inhibition zones of Honey at (a) 50%, (b) 80%, (c) 100% concentration and ethanolic extracts of <i>Aloevera</i> leaf gel.	124
31.	Fig. 4.14. Inhibition zones of Honey at (a) 50% (b) 80% (c) 100% concentration and 95% ethanolic extracts of <i>Aloevera</i> leaf gel.	124
32.	Fig. 4.15. Inhibition zones of Honey at (a) 50% (b) 80% (c) 100% concentration and 95% ethanolic extracts of <i>Aloevera</i> leaf gel	125
33.	Fig. 4.16 MIC of ethanolic extracts of selected plants against <i>E. coli</i>	128
34.	Fig. 4.17 MIC of ethanolic extracts of selected plants against <i>Staphylococcus aureus</i> .	129
35.	Fig. 4.18 MIC of ethanolic extracts of selected plants against <i>Pseudomonas aeruginosa</i>	131
36.	Fig. 4.19 MIC of ethanolic extracts of selected plants against <i>Proteus mirabilis</i>	132
37.	Fig. 4.20 MIC of ethanolic extracts of selected plants against <i>Candida albicans</i>	134
38.	Fig. 4.21 MIC of Honey against five tested diabetic wound associated pathogens	135
39.	Fig. 4.22. MIC of <i>Aloevera</i> gel ethanolic extract against five tested diabetic wound associated pathogens.	137
40.	Fig. 4.23. MIC of ethanolic extract of six selected plants against <i>Ecoli</i> (MTCC1610) Here, CL= <i>Curcuma longa</i> , PE= <i>Phyllanthus emblica</i> TB= <i>Terminalia Bellerica</i> , TC= <i>Terminalia chebula</i> , AI = <i>Azadirachta indica</i> ,CA= <i>Centella asiatica</i>	137
41.	Fig. 4.24. MIC of ethanolic extract of six selected plants against <i>S. aureus</i> , (MTCC3160) Here, CL= <i>Curcuma longa</i> , PE = <i>Phyllanthus emblica</i> TB = <i>Terminalia Bellerica</i> , TC= <i>Terminalia chebula</i> , AI = <i>Azadirachta indica</i> ,CA= <i>Centella asiatica</i>	138
42.	Fig. 4.25. MIC of ethanolic extract of six selected plants against <i>P. mirabilis</i> (MTCC425), Here, CL= <i>Curcuma longa</i> , PE= <i>Phyllanthus emblica</i> TB= <i>Terminalia Bellerica</i> , TC= <i>Terminalia chebula</i> , AI = <i>Azadirachta indica</i> ,CA= <i>Centella asiatica</i>	138
43.	Fig. 4.26. MIC of ethanolic extract of six selected plants against <i>C. albicans</i> (MTCC183) Here, CL= <i>Curcuma longa</i> , PE= <i>Phyllanthus emblica</i> TB= <i>Terminalia Bellerica</i> , TC= <i>Terminalia chebula</i> , AI = <i>Azadirachta indica</i> ,CA= <i>Centella asiatica</i>	139
44.	Fig. 4.27. MIC of Honey of against five diabetic wound associated pathogens , <i>E. coli</i> , (MTCC1610) , <i>Pseudomonas aeruginosa</i> (MTCC6458), <i>Staphylococcus aureus</i> , (MTCC3160) , <i>Proteus. Mirabilis</i> (MTCC425), <i>Candida albicans</i> (MTCC183)	139
45.	4.28. MIC of <i>Aloevera gel</i> ethanolic extract against five diabetic wound associated pathogens , <i>Escherichia coli</i> , (MTCC1610) , <i>Pseudomonas aeruginosa</i> (MTCC6458), <i>Staphylococcus aureus</i> , (MTCC3160) , <i>Proteus.</i>	140

	<i>Mirabilis (MTCC425), Candida albicans (MTCCI83)</i>	
46.	<b>Fig. 4.29 Wound area contraction in mm<sup>2</sup> in Group I, Group II, Group III, Group IV, Group V, Group VI from day 0 to post wounding day 18<sup>th</sup>.</b>	144
47.	<b>Fig. 4.30 Wound area contraction in mm<sup>2</sup> in Group- I Normal Control animals) treated with simple ointment base from day 0 to day 18<sup>th</sup>.</b>	144
48.	<b>Fig. 4.31 Wound area contraction in mm<sup>2</sup> in Group-II diabetic control animals treated with simple ointment base from day 0 to day 18th.</b>	145
49.	<b>Fig. 4.32 Wound area contraction in mm<sup>2</sup> in Group-III Diabetic experimental animals treated with formulation I from day 0 to day 18th.</b>	145
50.	<b>Fig. 4.33 Wound area contraction in mm<sup>2</sup> in Group-IV Diabetic experimental animals treated with formulation II from day 0 to 18th day.</b>	146
51.	<b>Fig. 4.34 Wound area contraction in mm<sup>2</sup> in Group-V Diabetic experimental animals treated with formulation III from day 0 to 18th day.</b>	146
52.	<b>Fig. 4.35 Wound area contraction in mm<sup>2</sup> in GroupVI reference ointment, povidone iodine treated group from day 0 to 18<sup>th</sup> day.</b>	147
53.	<b>Fig. 4.36 Percent wound contraction in Group I Normal control animals treated with simple ointment base.</b>	149
54.	<b>Fig. 4.37 Percent wound contraction in Group II Diabetic control animals treated with simple ointment base.</b>	149
55.	<b>Fig. 4.38 Percent wound contraction in Group III Diabetic experimental</b>	150

	<b>animals treated with test formulation I</b>	
<b>56.</b>	<b>Fig. 4.39 Percent wound contraction in Group IV Diabetic experimental animals treated with test formulation II</b>	150
<b>57.</b>	<b>Fig. 4.40 Percent wound contraction in Group V Diabetic experimental animals treated with test formulation III</b>	151
<b>58.</b>	<b>Fig. 4.41 Percent wound contraction in Group VI Diabetic animals treated with reference ointment (povidone iodine ointment).</b>	151
<b>59.</b>	<b>Fig. 4.42 Wound area contraction from day 0 to day 18th in diabetic control Group animals treated with simple ointment base.</b>	154-155
<b>60.</b>	<b>Fig. 4.43 Wound area contraction from day 0 to day 18th in diabetic experimental group animals treated with formulation I (10% <i>Aloevera</i> gel ethanolic extract ointment).</b>	156-157
<b>61.</b>	<b>Fig. 4.44 Wound area contraction in Group IV Diabetic experimental animals treated with test formulation II (15% <i>Triphala</i> extract ointment)</b>	158-159
<b>62.</b>	<b>Fig. 4.45 Wound area contraction in Group V Diabetic experimental animals treated with test formulation III (20% polyherbel extract ointment).</b>	160-161
<b>63.</b>	<b>Fig. 4.46 Wound area contraction in Group VI Diabetic animals treated with reference drug betadin (10% povidone iodine ointment).</b>	162-163
<b>64.</b>	<b>Fig. 4.47 Wound area contraction from day 0 to day 18 in normal control animals group treated with simple ointment base</b>	164-165

65.	<b>Fig. 4.48 Histological section of - Normal control group (treated by simple ointment base) showing multiple hair follicle, Grade-II vascularity, Grade-II fibrosis, Grade-II collagen fibers, Grade-I inflammatory cells.</b>	168
66.	<b>Fig. 4.49 Histological section of - Diabetic control group (treated by simple ointment base ) showing Grade-I vascularity, Grade-II fibrosis, Grade-I collagen fibers with fibro collagnous tissue, Grade-III inflammatory cells.</b>	168
67.	<b>Fig. 4.50 Histological section of - Reference group ( treated by povidone iodine ointment ) showing ,Grade-III vascularity,Grade-II fibrosis showing fibrocytes with elongated nucleus ,Grade-II collagen, Grade-II inflammatory cells showing lymphocytes and neutrophils.</b>	169
68.	<b>Fig. 4.51 Histological section of Diabetic experimental group (treated with formulation III polyherbal ointment) showing Grade-III Vascularity, Grade-III Fibrosis showing fibrocyes, Grade-III collagen, Grade-I Inflammatory cells.</b>	169
69.	<b>Figure 4.52 Histological section of Diabetic experimental group ( treated with test formulation II ) showing engrossed vascular channels with Grade-III vascularity ,Grade-II fibrosis, showing fibrocytes with elongated nucleus ,Grade-II collagen fibers , Grade-II inflammatory cells ,mature lymphocytes and neutrophils.</b>	170
70.	<b>Fig. 4.52 Histological section of - Diabetic experimental group ( treated by</b>	170

	<b>formulation I ) showing, Grade-II vascularity, Grade-II fibrosis, Grade-II collagen fibers , Grade-inflammatory cells</b>	
--	--	--

In conclusion, non-healing wounds require a systematic approach as well as the dedicated involvement of different medical specialties and professions, but internationally this remains a challenge to achieve. The current changes in the health care systems are not making this easier. Present problems in the use of local antimicrobial agents in non-healing wounds, European Medical Hygiene (EMH), February 2014. 11. Gottrup, F., et al., EWMA Document: Antimicrobials and Non-healing Wounds - Evidence, Controversies and Suggestions. J Wound Care, 2013. 22((5 suppl.)): p. 1-92. Further, wounds often produce exudate, the management of which is an important element of good. © EWMA. Science, Practice and Education.